Clinical trial
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone…
NCT00492089 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00492089 |
|---|---|
| Title | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer |
| Official title | A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Central Nervous System Germ Cell Tumor, Adult Choroid Plexus Tumor, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Grade II Meningioma and 77 more |
| Intervention type | Drug, Procedure |
| Interventions | bevacizumab, placebo, magnetic resonance imaging, quality-of-life assessment |
| Enrollment | 11 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Jun 27, 2007 |
| Last update posted | May 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: